Declan Doogan

Declan Doogan is a declared insider at 2 companies (board member); the most frequent names are Biohaven Pharmaceutical Holding Co Ltd. and Tenax Therapeutics, Inc. In total, 8 filings cover trades dated from 11 June 2020 to 16 September 2026.

On the open market, the record shows 1 purchase worth €88k and 3 sales worth €2.1M. On balance, insiders were net sellers of €2.0M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 option exercises. In 2026 alone, the filings show 1 purchase and no sales.

The latest filing, published on 17 September 2026, reports an open-market purchase of €88k in Tenax Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.